Neutrophil enhancement of *Pseudomonas aeruginosa* biofilm development: human F‐actin and DNA as targets for therapy

Quinn M. Parks,1 Robert L. Young,2 Katie R. Poch,1 Kenneth C. Malcolm,1 Michael L. Vasil3 and Jerry A. Nick1,2

1Department of Medicine, National Jewish Health, 1400 Jackson, Denver, CO, USA
2Division of Pulmonary Science and Critical Care Medicine, University of Colorado, 4200 E. 9th Ave, Denver, CO, USA
3Department of Microbiology, University of Colorado Denver Anschutz Medical Campus, 12800 E. 19th Ave, Aurora, CO, USA

In the cystic fibrosis (CF) airway, chronic infection by *Pseudomonas aeruginosa* results from biofilm formation in a neutrophil-rich environment. We tested the capacity of human neutrophils to modify early biofilm formation of *P. aeruginosa* strain PAO1, and an isogenic CF strain isolated early and years later in infection. In a static reactor, *P. aeruginosa* biofilm density of all strains was enhanced at 24 h in the presence of neutrophils, with the greatest relative increase associated with the lowest inoculum of *P. aeruginosa* tested. Previously, neutrophil‐induced biofilm enhancement was shown to largely result from the incorporation of F‐actin and DNA polymers into the bacterial biofilm. This finding was advanced by the comparison of biofilm enhancement from intact unstimulated neutrophils and from lysed or apoptotic neutrophils. Apoptotic neutrophils, with an intact cell membrane, were unable to contribute to biofilm enhancement, while lysed neutrophils evoked a similar response to that of intact cells. Using F‐actin and DNA as targets, the capacity of negatively charged poly(amino acids) to disrupt, or prevent, early biofilm formation was tested. Anionic poly(aspartic acid) effectively prevented or disrupted biofilm formation. Combination of poly(aspartic acid) with DNase resulted in a synergistic increase in biofilm disruption. These results demonstrate that the presence of dying neutrophils can facilitate the initial stages of biofilm development by low inocula of *P. aeruginosa*. Neutrophil F‐actin represents a potential new therapeutic target for disruption of pathogenic biofilms.

INTRODUCTION

Cystic fibrosis (CF) lung disease features persistent neutrophil accumulation within the airways from the time of infancy (Khan *et al.*, 1995). Inhalation of aerosolized *Pseudomonas aeruginosa* occurs frequently from environmental exposures, including dirt and contaminated water (Baumgartner & Grand, 2006; Burns *et al.*, 2001; Khan *et al.*, 2007). While eradication of *P. aeruginosa* is possible in childhood, persistent infection eventually occurs in over 80% of adult CF patients. Chronic *P. aeruginosa* infection is clearly linked with increased morbidity and mortality in CF (Emerson *et al.*, 2002; Parad *et al.*, 1999; Schaedel *et al.*, 2002), and is associated with phenotypic and genetic changes of the bacteria within the airway, including the formation of biofilms (Drenkard & Ausubel, 2002; Ernst *et al.*, 1999; Spencer *et al.*, 2003). In classical models, bacterial biofilms are surface‐attached communities of cells encased within a self‐produced extracellular polysaccharide matrix, often associated with mucoidy (Costerton *et al.*, 1999; Klausen *et al.*, 2003). However, biofilms in the CF airway are not typically surface‐associated, but rather are small aggregates of bacteria suspended in the highly tenacious CF sputum (Singh *et al.*, 2000; Sriramulu *et al.*, 2005).

Persistent accumulation of neutrophils in the CF airways, combined with ineffective clearance, leads to the uncoordinated release of DNA, actin and granule proteins from necrotic cells. This process results in mucus highly enriched with these products, all of which are clearly implicated in the pathogenesis of CF lung disease (Balfour‐Lynn, 1999; Khan *et al.*, 1995; Lethem *et al.*, 1990; Perks & Shute, 2000; Roum *et al.*, 1993; Sheils *et al.*, 1996). Previously, we have reported that the level of early biofilm formation by *P. aeruginosa* strain PAO1 is increased in the presence of neutrophils (Walker *et al.*, 2005). A principal mechanism...
of the enhancement is filaments of neutrophil-derived DNA and F-actin, which provide a ready framework for *P. aeruginosa* biofilm development (Walker *et al.*, 2005).

The F-actin and DNA framework formed following neutrophil necrosis is an attractive potential target for therapeutic intervention, as disrupting this scaffold could limit or decrease the integrity of an early *P. aeruginosa* biofilm. Negatively charged strands of DNA when present with F-actin are linked via positively charged histones and cations (Tang *et al.*, 2005). Recently it has been shown that polyanionic peptides have the capacity to disassociate DNA–histone, as well as F-actin–histone complexes, and disaggregate F-actin bundles (Tang & Janmey, 1996; Tang *et al.*, 2005). These findings suggest that a DNA-based biofilm that has incorporated F-actin could be disrupted by anionic polymers via electrostatic competition. Further, the addition of these anionic polymers could cooperatively enhance the activity of current therapies such as DNase.

**METHODS**

**Bacterial strains, media and culture conditions.** All *P. aeruginosa* strains were originated from stock plates of Luria broth (LB) agar, grown overnight in RPMI 1640 supplemented with l-glutamine and 2 % heat-inactivated (human) platelet-poor plasma (HIPPPr) at 37 °C with moderate shaking (225 r.p.m.) overnight, and frozen down to achieve consistent growth phase. All assays utilized bacteria grown overnight from the frozen stock in RPMI + 2 % HIPPPr at 37 °C. Cultures were then equilibrated in a Beckman DU 640 spectrophotometer to an OD_{600} of 0.30 (5 × 10^{8} c.f.u. ml^{-1}). Serial 10-fold dilutions of the cultures were performed in RPMI. Strains utilized were PAO1 (from B. H. Iglewski, University of Rochester, New York, USA) and an early and late strain isolated from a single patient days after initial infection, and following years of infection (Ogle *et al.*, 1987).

**Neutrophil isolation.** Neutrophils for all assays were isolated from healthy volunteers by the plasma Percoll method as previously described (Haslett *et al.*, 1985).

**Crystal violet (CV) biofilm assay.** Donor neutrophils were resuspended at a concentration of 16.6 × 10^{6} cells ml^{-1} in RPMI + 2 % HIPPPr in a Nunc round-bottom 96-well plate. The cellular control was a plate identical to the test plate, save for the absence of neutrophils. Dilutions of bacteria were tested at a 1 : 1 ratio to a 1 : 0.001 ratio, thus final concentrations of bacteria ranged from 16.6 × 10^{8} to 16.6 × 10^{6} c.f.u. ml^{-1}. A Nunc TSP lid system, which comprises a 96-well plate lid with pegs that extend into each well, was then placed on a 96-well plate. This assembly was then incubated for 24 h with rocking (3–4 oscillations min^{-1}) at 37 °C. At 24 h, the peg lids with bacterial biofilms were removed and rinsed for 2 min in sterile normal saline to remove non-adherent bacteria and cellular debris. The peg lid was air-dried for 5 min, then fixed for 10 min in 100 % ethanol. The ethernet was evaporated for 5 min on the bench top, then biofilms were stained in 1 % CV for 15 min. Excess CV was removed by two rinses in normal saline. Decolorization took place in a Nunc 96-well flat-bottom plate with 200 µl 100 % methanol per well for 45 min. Readings were taken in a μQuant plate reader using the KCjunior v1.403 software at 550 nm (BioTek Instruments). Values within control samples were averaged prior to comparison of each test well.

**Amino acid preparation.** Pure amino acid chains of multiple lengths were initially diluted in PCR grade dH_{2}O to 1 M, then serially diluted in normal saline. Peptides used were poly(L-aspartic acid) (Sigma) and poly(serine) (MP Biomedicals). No further purification was performed. Pulmozyme (DNase) (Genetech; NDC 50242-0100-40) was added at final concentrations of 33 µg DNase ml^{-1} or 8.25 µg DNase ml^{-1}. Protease inhibitors were used at final concentrations of 2.56 µg leupeptin ml^{-1}, 1.03 µg pepstatin A ml^{-1} and 2.56 µg aprotinin ml^{-1}.

**Quantification of viable bacteria within biofilm.** To quantify the density of biofilms formed under various conditions, biofilms were established on a Nunc TSP plate lid as described above. Pegs were rinsed in saline for 2 min, then placed in a 96-well round-bottom Nunc plate with 150 µl sterile saline and sonicated twice for 10 min in a Fisher FS 110 sonicator. Test wells were pooled and serially diluted for quantification by colony counts.

An alternative method was utilized to compare bacterial quantity by c.f.u. to quantification by metabolism via alamarBlue reduction. First, biofilms were established on a Nunc TSP 96-well plate lid as described above with 2.5 × 10^{6} bacteria (PMN to bacteria ratio of 1 : 0.01). Pegs were rinsed in saline for 2 min, then the lid was divided in half. Half the lid was treated with a combination of DNase and poly(L-aspartic acid) at concentrations of 66 µg DNase ml^{-1} and 5 µM, respectively, for 20 min. Following digestion, the contents of wells were removed, serially diluted in saline, and plated on LB agar. The treated and untreated lid halves were then placed into alamarBlue development medium (200 µl total well volume, comprising 130 µl RPMI 1640x, 50 µl 2 × LB broth and 20 µl alamarBlue (Invitrogen) in a Costar 3603 well plate (Corning)). Plates were read in a FLX 800 plate reader (BioTek instruments) every half hour for 24 h at 37 °C with shaking. Bacterial counts were derived from plotting the V_{50} of sample wells calculated by a Boltzmann sigmoidal non-linear regression against the V_{50} of standard curves generated by defined concentrations of bacteria that were plotted in a linear regression against log c.f.u.

**Neutrophil lysis and induction of apoptosis to induce biofilm growth.** To examine the role of available cellular constituents as well as living neutrophils in *P. aeruginosa* biofilm enhancement, we compared biofilm density in the presence of intact unstimulated neutrophils to that in the presence of lysed or apoptotic neutrophils. Lysed neutrophils were prepared the same way as living neutrophils, but were frozen and thawed (−80 °C for 15 min) once prior to addition of bacteria. Apoptosis was induced by suspending neutrophils at 2.0 × 10^{6} cells ml^{-1} in apoptosis buffer (137 mM NaCl, 2.7 mM KCl, 2 mM MgCl_{2}, 5 mM glucose, 10 mM HEPES pH 7.4, 0.05 % delipidated BSA) and UV irradiation (254 nm) on a Fotodyne 3-3000 UV transilluminator for 5 min. Cells were then incubated at 37 °C with shaking (30 r.p.m.) in conical polypropylene tubes. Apoptosis was determined using an aliquot of 2 × 10^{4} cells which were diluted and cytocentrifuged at 600 r.p.m. for 2 min on glass slides and stained with a modified Wright–Giemsa stain. Cells were counted as apoptotic if their nuclei lost segmentation and appeared round and darkly stained as described previously (Whitlock *et al.*, 2000). At least 200 cells were counted per slide in a blinded fashion until >80 % apoptosis had been reached. Biofilms were grown for 24 h after the addition of bacteria, then assessed by CV staining as detailed above.

**Light microscopy.** Intact, lysed and apoptotic neutrophils were prepared as described above and *P. aeruginosa* strain PA01 was added at a concentration ratio of 1 : 0.01 in an 18-well slide (total volume of 20 µl) (Ibidi). Slides were incubated at 37 °C for 30 min, then fixed with 1.3 % glutaraldehyde + 33.3 % ethanol at room temperature for 5 min. Fixative was removed and the slide was stained with a modified Wright–Giemsa stain. Slides were visualized on bright-field with an Axivert 200M microscope (Carl Zeiss) using a ×63 oil objective. Images were minimally level adjusted using Adobe Photoshop CS to show detail.

http://jmm.sgmjournals.org
Scanning electron microscopy (SEM). Biofilms of *P. aeruginosa* isolates (2.5 × 10^8 c.f.u.) were grown in the presence or absence of neutrophils (2.5 × 10^6) (PMN to bacteria ratio of 1:0.01) for 48 h. Pegs were rinsed briefly with 0.9% saline to remove non-biofilm-associated mass and were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) at 4 °C for 20 h. The pegs were then washed in 0.1 M cacodylate buffer for 10 min, and rinsed in ddH2O briefly. The pegs were then dehydrated in 70% ethanol for 15 min. Pegs were air-dried for a minimum of 72 h, removed from the TSP reactor with a hot scalpel, and affixed to carbon stubs with epoxy resin and allowed to dry. Following gold sputter coating, SEM was performed using a JEOL 5800LV scanning electron microscope at low and high magnifications to visualize both gross as well as fine detail. Images were contrast/brightness-adjusted in Adobe Photoshop CS. All images of biofilms grown without neutrophils had a despeckle filter minimally applied to reduce background.

**Validation of isogenic status of early and late CF *P. aeruginosa* isolates.** In order to confirm the lineage of the strains utilized in this report, a series of PCRs were run that amplify variable number tandem repeats (Onteniente et al., 2003). Briefly, this method amplifies tandem repeats of nucleotides of defined size that occur in variable number, which is related to lineage of the bacteria. Thus products of similar sizes indicate a closer lineage. Reaction conditions and primers were as described by Onteniente et al. (2003). *Taq* polymerase was Eppendorf MasterMix. Primers were purchased from IDT.

This assay resulted in seven of eight primers providing a product, and all of the reaction products of the early and late strains were identical (see Supplementary Fig. S1 in JMM Online). In all reactions, the CF early and late strains produced products of an identical size. Neither clinical strain produced a product from primer set 5915, indicating that this particular variable number tandem repeat was not present; however, a product was produced by PAO1 (Supplementary Fig. S1d). PAO1 produced differently sized products from the CF strain in all primer sets save 3496. Coupled with previously published pulse-field data (Ogle et al., 1987), we are satisfied that these strains represent isogenic bacteria that have been isolated both at initial colonization (environmental) as well as after prolonged infection from a child with CF (host-adapted).

**Statistical analysis.** Data were analysed using Prism 4 (Graphpad version 4.03) or Excel (Microsoft Office 2003). Student’s *t*-test was used to determine significance of paired data. One-way, and repeated measures ANOVA were performed on data where multiple testing resulted in datasets that required additional post-test analysis. Tukey’s post test, where all datasets are compared to each other, and Dunnett’s post test, where multiple datasets are compared to a single control set, were utilized as noted, with significance at a value no less than *P* < 0.05.

**RESULTS AND DISCUSSION**

*P. aeruginosa* biofilm density and quantity of associated bacteria are increased by the presence of human neutrophils

Human neutrophils isolated from healthy volunteers were combined with *P. aeruginosa* strain PAO1 (Fig. 1a), an early CF isolate (Fig. 1b) and an isogenic late CF isolate (Fig. 1c) over a range of bacteria to neutrophil ratios spanning 4 logs. All ratios of bacteria to neutrophils tested resulted in a significant (*P* < 0.05) enhancement of biofilm density when compared to *P. aeruginosa* of equal concentration grown in the absence of neutrophils, as measured by CV staining. To verify that neutrophil-induced increases in biofilm density also result in an increase in the bacterial population, we examined the metabolism of the biofilm with an alamarBlue reduction viability assay, and compared the results to biofilm density as quantified by CV staining. A similar pattern of neutrophil-induced biofilm enhancement was found to exist between methods (Supplementary Fig. S2). Further, bacterial counts calculated by alamarBlue assay were determined to be similar to those when biofilms were digested and plated (data not shown). In sum, these results indicate that the presence of human neutrophils enhances early biofilm density and quantity of

**Fig. 1.** *P. aeruginosa* biofilm formation is enhanced by human neutrophils. Biofilm density following 24 h of bacterial growth in the presence (open bars) or absence (black bars) of neutrophils. At time 0, a fixed inoculum of neutrophils (2.5 × 10^6) was combined with *P. aeruginosa* at a 1:1 ratio, and decreasing 10-fold concentrations of bacteria to 1:0.001. Strains examined were PAO1 (a), a clinical CF strain isolated early after initial infection (b) and an isogenic mucoid strain isolated from the same patient 4 years later (c). Biofilm formation was quantified by CV staining, with correlated absorbance presented on a log_{10} scale. Significance of the addition of neutrophils (*) was calculated by Student’s *t*-test at *P* < 0.05, with comparisons as noted. The results represent the means of 10 independent experiments.
bacteria. This effect was demonstrated with increases of *P. aeruginosa* biofilms from PAO1 as well as isogenic early and late CF isolates by orders of magnitude over that produced by the bacteria alone at 24 h.

Though intrinsically capable of forming biofilms, in the absence of neutrophils, decreasing initial concentrations of *P. aeruginosa* (inocula ranging from $2.5 \times 10^6$ to $2.5 \times 10^3$ c.f.u.) resulted in a significant decrease in biofilm density from each concentration to the next, save the two most dilute samples (Fig. 1a–c). Under the conditions tested, a basal level of biofilm formation is reached at an inoculum of $2.5 \times 10^4$ c.f.u. and decreasing the bacterial concentration further has no effect in decreasing uninduced biofilm density. This is of particular interest, as the initial inoculum of *P. aeruginosa* entering the CF airway is likely quite small.

Neutrophils are short-lived cells, and in the presence of *P. aeruginosa* rapidly progress to death via necrosis or apoptosis. Necrotic cell death features loss of cell membrane integrity and the uncoordinated release of nuclear and cytoplasmic contents. Programmed cell death via apoptosis proceeds through a coordinated series of steps, which results in nuclear fragmentation and intense chromatin condensation, but maintenance of a near-to-intact cytoplasmic membrane. We compared the level of biofilm induction resultant from combining bacteria with intact viable cells to that with lysed or apoptotic neutrophils. Within 30 min, many of the intact neutrophils had undergone lysis, and bacteria were seen to aggregate in the presence of necrotic debris (Fig. 2b). A similar effect was seen following 30 min of co-incubation with lysed neutrophils (Fig. 2c). In contrast, neutrophils induced to apoptosis prior to exposure to *P. aeruginosa* remained intact, and the bacteria remained dispersed (Fig. 2d). By 24 h, viable and lysed neutrophils induced equivalent levels of biofilm enhancement, but apoptotic neutrophils induced significantly less when compared to the live PMNs ($P <0.001$) (Fig. 2e). Together, these results demonstrate that apoptotic death of the neutrophil limits the availability of F-actin and DNA, which is required to enhance early *P. aeruginosa* biofilm formation. It is widely accepted that neutrophil apoptosis represents a beneficial response in reducing tissue injury from uncoordinated release of various cytotoxic components of the leukocyte. Our findings support the idea that in the presence of *P. aeruginosa*, neutrophil apoptosis also serves to limit the capacity of the pathogen to form a biofilm.

Biofilms of *P. aeruginosa* strain PAO1 (Fig. 3; Supplementary Fig. S3) as well as of the early and late CF strains (Supplementary Figs S4 and S5) were allowed to form in the presence of neutrophils, and compared by SEM to biofilms grown in the absence of neutrophils. The presence of neutrophils evoked clear differences. Neutrophil-induced biofilms largely covered each peg, while in the absence of neutrophils, only scattered aggregates of bacteria were visualized (Fig. 3; Supplementary Figs S3–S5). In addition, the architecture of the biofilm was dramatically thicker and more developed in the presence of neutrophils. Generally, all three strains followed similar patterns in uninduced and neutrophil-induced biofilm formation at 48 h.
Disruption of neutrophil-induced *P. aeruginosa* biofilms by anionic but not uncharged poly(amino acids)

Previously, we have shown that polymers of F-actin and DNA are neutrophil products that enhance biofilm formation (Walker *et al.*, 2005). Enhancement of *P. aeruginosa* biofilm development in the presence of neutrophils was lost in the presence of DNase, which enzymically depolymerizes DNA, and gelsolin, which severs F-actin into small fragments (Walker *et al.*, 2005). Recently it has been reported that anionic poly(amino acids) can dissolve negatively charged F-actin and DNA bundles that are electrostatically associated via positively charged histones and other multivalent cations (Tang *et al.*, 2005). Poly(aspartic acid) has a concentrated negative charge that has a twofold effect. Firstly, it sequesters the histone from the DNA and F-actin preventing it from serving as a charge linker between these two polymers (Tang *et al.*, 2005). Secondly, its acidic nature causes depolymerization of F-actin to G-actin (Tang & Janmey, 1996). We hypothesize that these actions could dismantles the early biofilm structure, as well as prevent initial formation or reformation after dissolution.

Peptides of equivalent length (median length of 74-mer) were compared for their capacity to disrupt a 24-h-old biofilm of *P. aeruginosa* formed in the presence of human neutrophils. Homopeptide chains of anionic (Asp)\(_{74}\) and a polar but uncharged (Ser)\(_{74}\) were analysed. When the 24 h biofilms were combined with these poly(amino acids) suspended in saline (free of neutrophil products not incorporated in the biofilm) for 3 h, a significant concentration-related disruption of biofilms occurred in response to (Asp)\(_{74}\) (Fig. 4a). The effect of the anionic peptide is dose-related, as there was a significant decrease in biofilm density as the concentration of (Asp)\(_{74}\) was increased from 5 to 10 \(\mu\)M (Fig. 4a). The polar but uncharged (Ser)\(_{74}\) did not cause disruption of the biofilm at either concentration (Fig. 4a).

**Effect of poly(amino acid) chain length on biofilm disruption**

To establish whether or not the biofilm-disrupting effect of negatively charged peptides is related to the length of the polymer chain, we compared the effect of longer charged polypeptides. Using equimolar concentrations, amino acid chains of 260 residues were compared to the 74-mer polypeptides to determine the effect of chain length on biofilm disruption. Under these conditions, (Asp)\(_{260}\) was more effective than (Asp)\(_{74}\) (Fig. 4b).

**Proteases reduce the capacity of charged poly(amino acids) to disrupt neutrophil-induced *P. aeruginosa* biofilms**

When poly(amino acids) were added directly to the milieu of necrotic neutrophils in which the biofilm was formed, the capacity of poly(amino acids) to disrupt biofilms was diminished (Fig. 5a) compared to reactions conducted in saline (Fig. 4). Under these conditions, neither (Asp)\(_{74}\) nor (Ser)\(_{74}\) was able to disrupt biofilms. Further, a similar effect was observed when the long-chain and short-chain poly(aspartic acid) were compared (Fig. 5b). As both neutrophils and *P. aeruginosa* contain and/or synthesize an array of proteases, which degrade peptide chains, we tested the capacity of a protease inhibitor cocktail to restore the potential of poly(amino acids) to disrupt the biofilm under...
four independent experiments. In the presence of protease inhibitors, there exists an even greater reduction in biofilm density increasing from 25% to 52% (Fig. 5c). When the biofilms were removed with a sevenfold greater concentration of protease inhibitors, the reduction in biofilm density was even greater at 10 μM (black bars). The uncharged (Ser)74 had no effect. (b) Using poly(amino acids) as a disruptant of neutrophil-induced biofilm; this effect was significantly greater at 10 μM (black bars). The uncharged (Ser)74 had no effect. (b) Using poly(amino acids) at a concentration of 5 μM, the longer (Asp)260 was more effective than the shorter (Asp)74. All assays are as measured by absorbance from CV staining. Significance (*) was calculated by one-way ANOVA followed by Dunnett’s post-test at P < 0.05 and (**) two-tailed t-test P < 0.05. The results represent the means of four independent experiments.

In the presence of protease inhibitors, (Asp)260 significantly disrupted the biofilm compared to the untreated control (Fig. 5c). With a sevenfold greater concentration of protease inhibitors, there exists an even greater restoration of the ability of (Asp)260 to disrupt biofilms, with a reduction in biofilm density increasing from 25% to 52% (Fig. 5c). When the biofilms were removed from the overnight culture material containing the products of necrotic neutrophils (such as proteases of bacterial and neutrophil origin), and washed once in saline, addition of (Asp)260 exhibited a significant disruptive effect, with no additional enhancement achieved by the addition of the protease inhibitor cocktail (Fig. 5d). These data support the conclusion that an anionic polypeptide can disrupt P. aeruginosa biofilms formed in the presence of human neutrophils, but proteolytic degradation, likely mediated by both bacteria and neutrophils, is a significant, though potentially solvable, obstacle to the use of poly(amino acids) in a neutrophil-rich environment.

Proteases in the lung environment are known to destroy a number of host defence mechanisms (Elkington et al., 2005; Roghanian et al., 2006), and the same seems to apply to poly(amino acids) in this system. A wide variety of modifications are now known that protect peptides from proteases, such as using D isomers or interspersing aspartic acid residues with non-naturally occurring amino acids. Studies by our group are under way to both protect the poly(aspartic acid) chain as well as to identify negatively charged polymers with greater intrinsic resistance to proteolytic degradation.

Fig. 4. P. aeruginosa biofilms induced by neutrophils are disrupted by electrostatically charged amino acid chains. (a) P. aeruginosa (strain PAO1) biofilms formed for 24 h in the presence of neutrophils were washed in saline and combined with poly(amino acids) of differing length and charge for 3 h at 37 °C. (Asp)74 at 5 μM (open bars) exhibited disruption of the biofilm; this effect was significantly greater at 10 μM (black bars). The uncharged (Ser)74 had no effect. (b) Using poly(amino acids) at a concentration of 5 μM, the longer (Asp)260 was more effective than the shorter (Asp)74. All assays are as measured by absorbance from CV staining. Significance (*) was calculated by one-way ANOVA followed by Dunnett’s post-test at P < 0.05 and (**) two-tailed t-test P < 0.05. The results represent the means of four independent experiments.

Ciprofloxacin and tobramycin are incapable of disrupting neutrophil-induced biofilms

Currently, the standard treatment for P. aeruginosa is antibiotics such as ciprofloxacin or tobramycin, although treatment with DNase has also been associated with decreased P. aeruginosa infectious load in the CF airway (Frederiksen et al., 2006; Gibson et al., 2003). In order to compare the relative effectiveness of polypeptides in dispersing P. aeruginosa biofilm in this system, we tested the ability of clinically relevant antibiotics to disrupt a biofilm induced by human neutrophils. P. aeruginosa biofilms (24-h-old) were exposed to twofold dilutions of either ciprofloxacin (Fig. 6a) or tobramycin (Fig. 6b) in clinically relevant concentrations ranging from 8 μg antibiotic ml−1 to 1024 μg antibiotic ml−1. The biofilm MIC was determined to be 128 μg antibiotic ml−1 and 256 μg antibiotic ml−1 for ciprofloxacin and tobramycin, respectively, under these conditions (data not shown). The biofilms were exposed for 3 h to antibiotics then quantified as described above with CV. Even under the highest concentration, the antibiotics tested demonstrated no capacity to disrupt the neutrophil-induced P. aeruginosa biofilm (Fig. 6), consistent with the well-established principle that conventional antibiotics are relatively less effective against biofilms (Costerton et al., 1987; Hoyle & Costerton, 1991; Prosser et al., 1987). Azithromycin, an antibiotic ineffective against planktonic P. aeruginosa, has been shown to have an antimicrobial effect against P. aeruginosa biofilms (Moskowitz et al., 2004), to retard biofilm development (Gillis & Iglewski, 2004), and to block quorum sensing and alginate polymer formation (Hoffmann et al., 2007). While azithromycin has not been shown to disrupt an established P. aeruginosa biofilm in vitro (Gillis & Iglewski, 2004), additional studies are warranted to fully define the anti-biofilm properties of this agent.

Anionic poly(amino acid) chains have the capacity to prevent P. aeruginosa biofilm formation

Although treatment of established P. aeruginosa biofilms likely represents the most relevant clinical scenario, in certain situations, biofilm formation is a highly predictable event. If agents existed that were effective in preventing the formation of the biofilm, strategies could be employed to reduce the potential for biofilm formation. We tested the capacity of (Asp)74 or (Ser)74 to inhibit biofilm development when added directly to a suspension of P. aeruginosa and neutrophils (Fig. 7). Biofilm development was quantified after 24 h incubation as detailed above. Uncharged (Ser)74 demonstrated no capacity to prevent biofilm formation, while (Asp)74 was significantly effective at preventing the formation of biofilms.

The robust activity of this amino acid chain, (Asp)74, in the prevention of biofilm formation led to the question of an alternative mechanism of disruption in this system. To address this, the toxicity or growth-enhancing effect of all the components used in the peptide assays was tested individually with P. aeruginosa and, when appropriate, in
Fig. 5. Proteolytic degradation reduces the capacity of charged poly(amino acids) to disrupt neutrophil-induced *P. aeruginosa* biofilms. (a) When poly(amino acids) of differing concentration were combined with a neutrophil-induced 24 h *P. aeruginosa* biofilm in the presence of overnight culture material (OCM), there was no significant effect on biofilm disruption at 5 μM (open bars) or 10 μM (black bars). (b) Under identical conditions, when the capacity of (Asp)74 and (Asp)260 to disrupt biofilms was tested there was not a significant effect in the presence of OCM. (c) When (Asp)260 (open bars) was combined with a protease inhibitor cocktail (black bars) in the presence of the OCM, a significant disruption of the biofilm was achieved, which was further increased when the protease inhibitor concentration was increased to sevenfold (crosshatched bars). (d) When the biofilms were removed from the OCM and washed once in saline, (Asp)260 exhibited a significant disruptive effect (open bar). No enhancement was achieved by the addition of a protease inhibitor cocktail (black bars) following removal of the neutrophil cellular milieu. All assays are as measured by absorbance from CV staining. Significance (*) was calculated by one-way ANOVA followed by Dunnett's post-test at P<0.05 and (**) two-tailed t-test P<0.05. The results represent the means of three independent experiments.

Fig. 6. Neutrophil-induced *P. aeruginosa* biofilms are not disrupted by anti-pseudomonal antibiotics. Neutrophil-induced PAO1 biofilms formed at a 1:0.01 ratio of bacteria to neutrophils were exposed to the antibiotics ciprofloxacin (a) or tobramycin (b) for 3 h at 37 °C at concentrations ranging from 8 to 1024 μg ml⁻¹. The biofilm density was then quantified by CV staining. No disruption of the biofilm was observed in response to either antibiotic over the range of dilutions tested. An untreated biofilm, as well as a media-only control, were included to serve as a reference of biofilm formation and background staining. Both assays are as measured by absorbance from CV staining. No significant differences were observed as calculated by the Kruskal–Wallis test followed by Dunn’s post-test to the untreated biofilm at P<0.05. The results represent the means of three independent experiments.
We found that within assays, the amount of bacteria recovered from pooled wells was consistent, and that neither (Asp)$_{74}$ nor (Ser)$_{74}$ displayed enhanced growth or bactericidal properties (not shown). In addition, the protease inhibitors pepstatin A, leupeptin and aprotinin alone or in combination displayed no antimicrobial effect.

DNase disrupts *P. aeruginosa* biofilms, and prevents their formation in the presence of neutrophils

Previously, our group and others have shown the capacity of DNase to disrupt *P. aeruginosa* biofilms (Frederiksen *et al.*, 2006; Walker *et al.*, 2005; Whitchurch *et al.*, 2002), supporting the concept that DNA is also an essential component of the ‘scaffolding’. Under the conditions used in Fig. 4, exposure to DNase for 3 h disrupts 24-h-old neutrophil-induced biofilms (Fig. 8a). Likewise, DNase was able to significantly prevent biofilm formation in the presence of neutrophils (Fig. 7b), under the conditions described for Fig. 7. In contrast, RNase demonstrated no capacity to disrupt (Fig. 8a) or prevent (Fig. 8b) biofilm formation.

Poly(aspartic acid) works in conjunction with DNase to disrupt biofilms

While concentrated DNase (Fig. 8a) or poly(aspartic acid) (Fig. 4) are both capable of disrupting an early biofilm over the course of a 3 h exposure, during DNase therapy in the CF airway it is likely that biofilms are exposed to DNase over a wide range of concentrations, and the effective duration of exposure may be quite brief. Furthermore, in the setting of chronic infections, biofilms are likely more than 24 h old. We tested the capacity of DNase and (Asp)$_{260}$ to disrupt biofilms when administered over a shorter period, at lower concentrations, and with thicker and more mature biofilms.

When the duration of exposure to DNase was reduced to only 10 min, a 24-h-old neutrophil-induced biofilm was still reduced by 75 % (Fig. 9a). However, a biofilm grown for 48 h was reduced by only 42 % by 10 min of DNase treatment (Fig. 9b). Likewise, biofilms at later stages of growth (48 h) also had greater resistance to disruption with (Asp)$_{260}$ and DNase; however, in combination these agents were effective in disrupting biofilms ($P < 0.01$).

Exposing a 24 h neutrophil-induced biofilm for only 10 min to (Asp)$_{260}$ resulted in a 49 % reduction in biofilm density (Fig. 9a). When DNase was used in combination with (Asp)$_{260}$, the mixture resulted in an 82 % reduction (Fig. 9a). (Asp)$_{260}$ alone could not reduce the density of a more mature 48 h biofilm, but when used in conjunction with DNase, (Asp)$_{260}$ was able to reduce the biofilm by 78 % (Fig. 8b).

The combined effect of (Asp)$_{260}$ with DNase was dose-dependent (Fig. 9c). By decreasing DNase concentration fourfold (8.25 µg DNase ml$^{-1}$), only a 16 % decrease in the biofilm density of a 48 h biofilm was achieved after 10 min treatment (Fig. 9c), compared to 42 % at the 33 µg DNase ml$^{-1}$ concentration (Fig. 9b). When the lower concentration of DNase was used in combination with (Asp)$_{260}$, the density of the biofilm was reduced by 67 % (Fig. 9c), demonstrating a strong synergistic effect between the

http://jmm.sgmjournals.org
enzyme and poly(aspartic acid). Thus, under conditions in which DNase as a single agent has little effect, the presence of (Asp)$_{260}$ significantly enhances the capacity of DNase to disrupt a biofilm formed in the presence of neutrophils. Parallel experiments were conducted with the early and late CF strains. Neutrophil-induced biofilms of the early CF strain (24 h of growth) were not disrupted by a 10 min exposure to DNase (Supplementary Fig. S6a), while the late CF strain demonstrated a modest disruption (Supplementary Fig. S6c). However, for both strains, the effect of DNase was significantly increased by the addition of (Asp)$_{260}$ (Supplementary Fig. S6a, c). The synergistic effect of DNase and (Asp)$_{260}$ was also apparent following 48 h of biofilm growth for both the early and late CF strains (Supplementary Fig. S6b, d). Perhaps of greatest clinical interest were attempts to disrupt the mucoid late CF strain that had been allowed to form for 48 h in the presence of neutrophils (Supplementary Fig. S6d). Under these conditions, only the combination of DNase and (Asp)$_{260}$ achieved significant disruption of the biofilm (Supplementary Fig. S6d).

The markedly decreased DNase effect in the context of the treatment of thicker 48 h biofilms, or with a mucoid strain of *P. aeruginosa* recovered later in CF infection, likely reflects an increased polysaccharide concentration that may obscure DNA cleavage sites. However, the synergistic effect of DNase with poly(aspartic acid) may stem from the capacity of poly(aspartic acid) to sequester histones as well as disassociating F-actin along with associated bacteria and saccharides, allowing DNase exposure to a greater number of sites for cleavage in the actin–DNA polymer. The CF airway is particularly vulnerable to *P. aeruginosa* infection, where these bacteria are able to survive indefinitely in the presence of an exuberant recruitment of neutrophils. Necrosis of the short-lived neutrophil occurs consistently and rapidly, while clearance of the cellular debris is ineffective, resulting in the enrichment of already viscous mucus with both DNA and F-actin (Lethem *et al.*, 1990; Rubin, 2007; Sheils *et al.*, 1996). Additional DNA of bacterial origin is present in the CF airway as well (Lethem *et al.*, 1990). The production of a *P. aeruginosa* biofilm is based on the association of the bacteria with a matrix, either self-produced or exogenously provided (Costerton *et al.*, 1999; Hentzer *et al.*, 2001; Sriramulu *et al.*, 2005). In humans, focal infection by *P. aeruginosa*, and subsequent biofilm formation, always

![Fig. 9. Poly(aspartic acid) works in cooperation with DNase to disrupt neutrophil-induced *P. aeruginosa* biofilms. PAO1 biofilms were allowed to form for 24 or 48 h in the presence of neutrophils at a 1:0.01 ratio of bacteria to neutrophils. The biofilms were then washed in saline and exposed to either poly(aspartic acid) alone (open bars) or combined with DNase (black bars). In all experiments, exposure to DNase and/or poly(aspartic acid) was for 10 min at 37 °C in saline. (a) As single agents, (Asp)$_{260}$ (5 μM) and 33 μg DNase ml$^{-1}$ effectively disrupted 24-h-old biofilms. (b) Using a 48 h biofilm, 33 μg DNase ml$^{-1}$, but not (Asp)$_{260}$ (5 μM), was effective as a single agent. However, a significant increase in biofilm disruption was achieved when (Asp)$_{260}$ was combined with DNase. (c) Using a 48 h biofilm and a lower concentration of 8.25 μg DNase ml$^{-1}$, a synergistic effect of (Asp)$_{260}$ (5 μM) and DNase was achieved. Assay is as measured by absorbance from CV staining. Significance (*) was calculated by one-way ANOVA followed by Dunnett’s post-test at $P < 0.05$ and (**) two-tailed t-test $P < 0.05$. The results represent the means of three independent experiments.](image-url)
occurs in association with an exuberant inflammatory response. *P. aeruginosa* infection of wounds, burns or the cornea of contact lens wearers occurs only after neutrophils have accumulated at the site of injury. In the case of the CF airway, the released chromosomal DNA with associated histones and F-actin provide a ready framework for *Pseudomonas* to occupy and proliferate. Strands of negatively charged DNA polymerize with negatively charged F-actin filaments by interaction with positively charged species such as histones and cations. *P. aeruginosa* associates in turn with this structure by binding either DNA or F-actin (van Schaik et al., 2005; Walker et al., 2005).

The presence of a framework of neutrophil DNA and F-actin may help to explain the efficacy of inhaled DNase in CF, which is associated with a decrease in infectious burden or frequency of pulmonary exacerbations (Frederiksen et al., 2006; Robinson, 2002). While improved sputum clearance is generally beneficial in controlling CF airway infection, the potential of DNase may be more fully realized by the addition of anionic polymers to disrupt biofilms in vivo. We have demonstrated that the presence of abundant F-actin and DNA in a neutrophil-rich environment is exploited by *P. aeruginosa* to ensure survival via biofilm development. Thus accounting for the incorporation of neutrophil products into the medically relevant *P. aeruginosa* biofilm is a logical advancement in our understanding of this extraordinary pathogen. It is conceivable that strategies to disrupt F-actin, as an adjunct to treatment with DNase and antibiotics, will represent an incremental improvement in our approach to treating chronic *P. aeruginosa* infection in the CF airway.

**ACKNOWLEDGEMENTS**

This work was supported by the following grants and foundations: HL090991 and HL34303 from the National Institutes of Health, a Cystic Fibrosis Foundation Research Grant (NICK07G0), The Rebecca Runyon Bryan Chair in Cystic Fibrosis, Colorado Bioscience Discovery Evaluation Grant and The Max and Yetta Karaski Foundation.

**REFERENCES**

Balfour-Lynn, I. M. (1999). The protease-antiprotease battle in the cystic fibrosis lung. *J R Soc Med* 92 (Suppl. 37), 23–30.

Baumgartner, A. & Grand, M. (2006). Bacteriological quality of drinking water from dispensers (coolers) and possible control measures. *J Food Prot* 69, 3043–3046.

Burns, J. L., Gibson, R. L., McNamara, S., Yim, D., Emerson, J., Rosenfeld, M., Hiatt, P., McCoy, K., Castile, R. & other authors (2001). Longitudinal assessment of *Pseudomonas aeruginosa* in young children with cystic fibrosis. *J Infect Dis* 183, 444–452.

Costerton, J. W., Cheng, K. J., Geesey, G. G., Ladd, T. I., Nickel, J. C., Dasgupta, M. & Marrie, T. J. (1987). Bacterial biofilms in nature and disease. *Annu Rev Microbiol* 41, 435–464.

Costerton, J. W., Stewart, P. S. & Greenberg, E. P. (1999). Bacterial biofilms: a common cause of persistent infections. *Science* 284, 1318–1322.

Drenkard, E. & Ausubel, F. M. (2002). *Pseudomonas* biofilm formation and antibiotic resistance are linked to phenotypic variation. *Nature* 416, 740–743.

Elkington, P. T., O’Kane, C. M. & Friedland, J. S. (2005). The paradox of matrix metalloproteinases in infectious disease. *Clin Exp Immunol* 142, 12–20.

Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B. & Gibson, R. L. (2002). *Pseudomonas aeruginosa* and other predictors of mortality and morbidity in young children with cystic fibrosis. *Pediatr Pulmonol* 34, 91–100.

Ernst, R. K., Yi, E. C., Guo, L., Lim, K. B., Burns, J. L., Hackett, M. & Miller, S. I. (1999). Specific lipopolysaccharide found in cystic fibrosis airway *Pseudomonas aeruginosa*. *Science* 286, 1561–1565.

Frederiksen, B., Pressler, T., Hansen, A., Koch, C. & Hoiby, N. (2006). Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. *Acta Paediatr* 95, 1070–1074.

Gibson, R. L., Burns, J. L. & Ramsey, B. W. (2003). Pathophysiology and management of pulmonary infections in cystic fibrosis. *Am J Respir Crit Care Med* 168, 918–951.

Gillis, R. J. & Igleswki, B. H. (2004). Azithromycin retards *Pseudomonas aeruginosa* biofilm formation. *J Clin Microbiol* 42, 5842–5845.

Haslett, C., Guthrie, L. A., Kopaniak, M. M., Johnston, R. B., Jr & Henson, P. M. (1985). Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. *Am J Pathol* 119, 101–110.

Hentzer, M., Teitzel, G. M., Balzer, G. J., Heydorn, A., Molin, S., Givskov, M. & Parsek, M. R. (2001). Alginate overproduction affects *Pseudomonas aeruginosa* biofilm structure and function. *J Bacteriol* 183, 5395–5401.

Hoffmann, N., Lee, B., Hentzer, M., Rasmussen, T. B., Song, Z., Johansen, H. K., Givskov, M. & Hoiby, N. (2007). Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of *Pseudomonas aeruginosa* and attenuates chronic *P. aeruginosa* lung infection in C57/1−/− mice. *Antimicrob Agents Chemother* 51, 3677–3687.

Hoyle, A. D. & Costerton, J. W. (1991). Bacterial resistance to antibiotics: the role of biofilms. *Prog Drug Res* 37, 91–105.

Khan, T. Z., Wagener, J. S., Bost, T., Martinez, J., Accurso, F. J. & Riches, D. W. (1995). Early pulmonary inflammation in infants with cystic fibrosis. *Am J Respir Crit Care Med* 151, 1075–1082.

Khan, N. H., Ishii, Y., Kimata-Kino, N., Esaki, H., Nishino, T., Nishimura, M. & Kogure, K. (2007). Isolation of *Pseudomonas aeruginosa* from open ocean and comparison with freshwater, clinical, and animal isolates. *Microb Ecol* 53, 173–186.

Klausen, M., Heydorn, A., Ragaas, P., Lambertsen, L., Aaes-Jorgensen, A., Molin, S. & Tolker-Nielsen, T. (2003). Biofilm formation by *Pseudomonas aeruginosa* wild type, flagella and type IV pili mutants. *Mol Microbiol* 48, 1511–1524.

Lethem, M. I., James, S. L., Marriott, C. & Burke, J. F. (1990). The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. *Eur Respir J* 3, 19–23.

Moskowitz, S. M., Foster, J. M., Emerson, J. & Burns, J. L. (2004). Clinically feasible biofilm susceptibility assay for isolates of *Pseudomonas aeruginosa* from patients with cystic fibrosis. *J Clin Microbiol* 42, 1915–1922.

Ogle, J. W., Janda, J. M., Woods, D. E. & Vasil, M. L. (1987). Characterization and use of a DNA probe as an epidemiological marker for *Pseudomonas aeruginosa*. *J Infect Dis* 155, 119–126.

Onteniente, L., Brisse, S., Tassios, P. T. & Vergnaud, G. (2003). Evaluation of the polymorphisms associated with tandem repeats for *Pseudomonas aeruginosa* strain typing. *J Clin Microbiol* 41, 4991–4997.
Parad, R. B., Gerard, C. J., Zurakowski, D., Nichols, D. P. & Pier, G. B. (1999). Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. *Infect Immun* 67, 4744–4750.

Perks, B. & Shute, J. K. (2000). DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics. *Am J Respir Crit Care Med* 162, 1767–1772.

Prosser, B. L., Taylor, D., Dix, B. A. & Cleeland, R. (1987). Method of evaluating effects of antibiotics on bacterial biofilm. *Antimicrob Agents Chemother* 31, 1502–1506.

Robinson, P. J. (2002). Dornase alfa in early cystic fibrosis lung disease. *Pediatr Pulmonol* 34, 237–241.

Roghanian, A., Drost, E. M., MacNee, W., Howie, S. E. & Sallenave, J. M. (2006). Inflammatory lung secretions inhibit dendritic cell maturation and function via neutrophil elastase. *Am J Respir Crit Care Med* 174, 1189–1198.

Roum, J. H., Buhl, R., McElvaney, N. G., Borok, Z. & Crystal, R. G. (1993). Systemic deficiency of glutathione in cystic fibrosis. *J Appl Physiol* 75, 2419–2424.

Rubin, B. K. (2007). Mucus structure and properties in cystic fibrosis. *Paediatr Respir Rev* 8, 4–7.

Schaezel, C., de Monestrol, I., Hjalte, L., Johannessen, M., Kornfalt, R., Lindblad, A., Strandvik, B., Wahlgren, L. & Holmberg, L. (2002). Predictors of deterioration of lung function in cystic fibrosis. *Pediatr Pulmonol* 33, 483–491.

Sheils, C. A., Kas, J., Travassos, W., Allen, P. G., Janmey, P. A., Wohl, M. E. & Stossel, T. P. (1996). Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. *Am J Pathol* 148, 919–927.

Singh, P. K., Schaefer, A. L., Parsek, M. R., Moninger, T. O., Welsh, M. J. & Greenberg, E. P. (2000). Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. *Nature* 407, 762–764.

Spencer, D. H., Kas, A., Smith, E. E., Raymond, C. K., Sims, E. H., Hastings, M., Burns, J. L., Kaul, R. & Olson, M. V. (2003). Whole-genome sequence variation among multiple isolates of *Pseudomonas aeruginosa*. *J Bacteriol* 185, 1316–1325.

Sriramulu, D. D., Lunnsdorf, H., Lam, J. S. & Römling, U. (2005). Microcolony formation: a novel biofilm model of *Pseudomonas aeruginosa* for the cystic fibrosis lung. *J Med Microbiol* 54, 667–676.

Tang, J. X. & Janmey, P. A. (1996). The polyelectrolyte nature of F-actin and the mechanism of actin bundle formation. *J Biol Chem* 271, 8556–8563.

Tang, J. X., Wen, Q., Bennett, A., Kim, B., Sheils, C. A., Bucki, R. & Janmey, P. A. (2005). Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. *Am J Physiol Lung Cell Mol Physiol* 289, L599–L605.

van Schaik, E. J., Giltner, C. L., Audette, G. F., Keizer, D. W., Bautista, D. L., Slupsky, C. M., Sykes, B. D. & Irvin, R. T. (2005). DNA binding: a novel function of *Pseudomonas aeruginosa* type IV pili. *J Bacteriol* 187, 1455–1464.

Walker, T. S., Tomlin, K. L., Worthen, G. S., Poch, K. R., Lieber, J. G., Saavedra, M. T., Fessler, M. B., Malcolm, K. C., Vasil, M. L. & Nick, J. A. (2005). Enhanced *Pseudomonas aeruginosa* biofilm development mediated by human neutrophils. *Infect Immune* 73, 3693–3701.

Whitchurch, C. B., Tolker-Nielsen, T., Ragas, P. C. & Mattick, J. S. (2002). Extracellular DNA required for bacterial biofilm formation. *Science* 295, 1487.

Whitlock, B. B., Gardai, S., Fadok, V., Bratton, D. & Henson, P. M. (2000). Differential roles for $\gamma\delta T$ integrin clustering or activation in the control of apoptosis via regulation of Akt and ERK survival mechanisms. *J Cell Biol* 151, 1305–1320.